[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338259-105":59,"doc-detail-338259-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unveiling-the-comorbidity-burden-of-male-breast-cancer","Unveiling the comorbidity burden of male breast cancer","","Male breast cancer (MBC) is a rare condition and may differ meaningfully from female breast cancer (FBC) in diagnosis timing, clinical characteristics, and genetic background. Using the EpiChron Cohort and logistic models, researchers evaluated comorbidities among prevalent breast cancer patients diagnosed between 2010 and 2019. Across 105 MBC and 11,657 FBC patients, MBC showed higher mean diagnosis age and a different comorbidity pattern, with cardiometabolic coexisting diseases more prominent in MBC. After year-by-birth matching, four associations persisted, including lipid metabolism disorder, genitourinary symptoms, anxiety disorders, and osteoporosis. Results support the need for tailored management strategies for MBC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unveiling-the-comorbidity-burden-of-male-breast-cancer/338259/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unveiling-the-comorbidity-burden-of-male-breast-cancer/338259.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why can male breast cancer differ from female breast cancer?","Question",{"text":112,"@type":113},"Male breast cancer is rare and shows distinct characteristics compared with female breast cancer, including differences such as later diagnosis stage and different genetic makeup.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data and study period were used to assess comorbidities?",{"text":117,"@type":113},"A retrospective observational study in the EpiChron Cohort selected prevalent breast cancer patients diagnosed between 2010 and 2019.",{"name":119,"@type":110,"acceptedAnswer":120},"Which comorbidity associations remained after year-by-birth matching?",{"text":121,"@type":113},"After matching, four associations remained: disorder of lipid metabolism, genitourinary symptoms and ill-defined conditions, anxiety disorders, and osteoporosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338259,1790989594,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nUnveiling the comorbidity burden of male breast cancer  \nAlejandro Santos-Mejías1,2􀀍, Aida Moreno-Juste1,2,3, Clara Laguna-Berna1,2, Beatriz Poblador-Plou1,2, DanielAparicio-Lopéz4, María Carmen Casamayor Franco4, Reyes Ibañez Carreras4 & Antonio Gimeno-Miguel1,2  \nMale breast cancer (MBC) is a rare condition with unique characteristics compared to female breast cancer (FBC). Despite its scarceness, there is growing evidence that MBC should not be studied and treated as FBC due to factors like later diagnosis stage and distinct genetic makeup. Retrospective observational study in the EpiChron Cohort, selecting all the prevalent patients with breast cancer between 2010 and 2019. Logistic models were used to determine associated comorbidities. Between 2010 and 2019, 105 MBC and 11,657 FBC patients were found in the EpiChron Cohort. MBC patients had a high mean age at diagnosis and number ofcomorbidities. Paying attention to comorbidity prevalences in breast cancer patients, it was clear that MBC patients tended to be prone to cardiometabolic coexisting diseases, while FBC patients were more prone to hormone-, bone-and mental diseases. There were nine chronic conditions associated to MBC patients, but after a year-by-birth matching only four associations remained. Two of them were associated previously [odds ratio (95% confidence interval)]: “Disorder of lipid metabolism” [1.65 (1.03–2.64)] and “Genitourinary symptoms and ill-defined conditions” [2.03 (1.07–3.87)]; and the other two were new,“Anxiety disorders” [2.05 (1.09–3.87)] and “Osteoporosis” [3.58 (1.26–10.14)]. After comparing associated comorbidities in FBC with those in MBC, it seems MBC patients share some of them, but they have their own particular set of coexisting diseases. In fact, once a year-by-birth matching was performed in MBC patient cohort, it was more obvious MBC comorbidities behave more similar to none-Breast-Cancer male population than to FBC patients. These findings highlight the distinct characteristics of the MBC patient population and the need for a tailored approach of managing MBC.  \nKeywords Male breast cancer, Comorbidity, Breast cancer, Co-existing conditions, Clinical characteristics, Clinical feature  \nMale Breast cancer (MBC) is a rare condition, it accounts for less than 1% of all breast cancer in Spain and worldwide, as with Female Breast cancer (FBC) its incidence rate is steadily rising on an annual basis1–3. Due to its low prevalence, there is a lacking in prospective randomized clinical studies; historically male patients have been excluded from breast cancer clinical trials. Our current knowledge of MBC come from small retrospective studies, this is one of the reasons why MBC has been traditionally considered an analogous clinical entity to menopausal FBC4,5.  \nAll the above has hampered to obtain useful and realistic knowledge regarding MBC characteristics and management, currently most treatment recommendations are extrapolated from FBC guidelines6. Nonetheless, there is an increasing evidence that MBC embodies its own distinct clinical identity, which requires its own particular considerations4,5,7. In fact, two specific histological subtypes have been described in MBC8, further supporting the aforementioned.  \nMost of the efforts for a better understanding of MBC have been focused to characterize sociodemographic, life-style and clinical differences between MBC and FBC patients and how those differences are associated tosurvivability and mortality. There are certain features of MBC well described in the literature. For instance, MBC patients tend to be diagnosed at older age, with a more advance tumour stage, with higher number of co-existing pathologies and with hormone-positive phenotype in comparison with their female counterparts. In reality, most of MBC patients are usually progesterone positive, estrogen positive and epidermal growth factor recept","cbCaiipB27BmW4Lx","https://ap.wps.com/l/cbCaiipB27BmW4Lx","pdf",2029152,14,"English","# Introduction\n# Study design and comorbidity modeling\n# Comorbidity patterns in MBC vs FBC\n# Clinical implications","[{\"question\":\"Why can male breast cancer differ from female breast cancer?\",\"answer\":\"Male breast cancer is rare and shows distinct characteristics compared with female breast cancer, including differences such as later diagnosis stage and different genetic makeup.\"},{\"question\":\"What data and study period were used to assess comorbidities?\",\"answer\":\"A retrospective observational study in the EpiChron Cohort selected prevalent breast cancer patients diagnosed between 2010 and 2019.\"},{\"question\":\"Which comorbidity associations remained after year-by-birth matching?\",\"answer\":\"After matching, four associations remained: disorder of lipid metabolism, genitourinary symptoms and ill-defined conditions, anxiety disorders, and osteoporosis.\"}]","Unveiling the comorbidity burden of male breast cancer | PDF",1790022798,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52e2ca7620ebd75921b428b2bab84067.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08c17890349dfc26db2badd4df681bab.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edc3175e6b4bec02329b52f4879c2610.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a16995360053fc86906b8a0ea6717d0.webp",980,1287]